IBA (Ion Beam Applications)

Overview

Founded in 1986 and headquartered in Louvain-la-Neuve in Wallonia, IBA develops particle accelerator technology with a primary focus on proton therapy systems used for cancer treatment. The company is the global market leader in proton therapy, with systems installed in major oncology centers worldwide.

IBA is listed on Euronext Brussels and generates approximately EUR 350M in annual revenue, with a workforce exceeding 1500 people. Its core technology converts cyclotron-based particle acceleration into clinical-grade cancer treatment equipment.

Beyond oncology, IBA also develops accelerator solutions for industrial applications including radiation processing and sterilization. The company represents one of Belgium's oldest and most substantial deep-tech companies, with a track record spanning four decades.